Apnimed restates its second quarter after misclassifying an $85.4 million gain on its sale to Shionogi
November 16, 2026 | prices as of the November 13 close
Apnimed, a US company developing an oral drug for obstructive sleep apnea, said on November 13 that it would restate its April to June financial statements. It had reported the $85.4 million gain from selling its stake in a joint venture to Shionogi as part of continuing operations, when it should have been reported in discontinued operations.
In short, the prospectus said which line this gain would go on, the first quarterly report after the listing put it on a different line, and the company has now corrected it.
Financial statements separate the results of the businesses a company keeps from those of businesses it has sold or otherwise disposed of, so that readers can see the earnings power that continues. The company says the correction does not change revenue, income or loss from operations, total net income, cash, or net cash flows. What changes is the split: for April to June, net income from continuing operations goes from $126.1 million to $40.7 million, and discontinued operations, which had carried an $0.2 million loss from the joint venture, now show net income of $85.2 million. Total net income stays at $125.9 million.
What the prospectus had said
Two passages in the prospectus dated July 30, 2026 bear on this. The first said that upon the disposition of the joint venture stake, the corresponding non-recurring gain would be classified within discontinued operations. The restatement puts the gain where that sentence said it would go.
The second disclosed a material weakness in internal control over financial reporting that the company was working to remediate. A material weakness is a deficiency that creates a reasonable possibility that a material misstatement will not be prevented or detected on a timely basis. Among its elements, the prospectus listed a lack of sufficient accounting personnel to maintain proper controls over the classification, valuation and disclosure of non-routine or complex transactions.
The amended quarterly report says the error was identified while the company was preparing its July to September report, and that management concluded the restatement is attributable to the previously disclosed material weakness. It says no additional material weakness was identified. According to the same day's 8-K, the company has hired five employees since filing the original report to strengthen its accounting function and internal controls. It says management is still assessing the effect of the restatement on its internal control over financial reporting.
Our article on Apnimed's prospectus
The sale to Shionogi
The gain in question came from selling Apnimed's 50% stake in Shionogi-Apnimed Sleep Science, a joint venture formed with Shionogi in November 2023, to Shionogi on April 6, 2026. According to the prospectus, Apnimed received $100.0 million in cash up front. Shionogi is also an Apnimed shareholder; its November 4 filing reported 7.10% of the common stock as of September 30.
Apnimed filed its July to September quarterly report on November 16. Its nine-month income statement puts the $85.4 million gain in discontinued operations. The risk factor on the material weakness was also reworded. The prospectus said that a failure to remediate it may adversely affect the company's ability to accurately and timely report its financial results. The new report says it "has in the past and may in the future" do so, and cites the restatement as an example. The company concluded that its disclosure controls were not effective as of September 30.
How the scoreboard moved
On our scoreboard, $1,000 put into each of the eleven companies in the Recent listings group at its first-day closing price comes to $9,422 as of the November 13 close. For Freenome, we count from the day its SPAC merger closed. A week earlier, at the November 6 close, the total was $9,257. The same amount put into the S&P 500 total return index on each of those listing days would be $11,515 as of the November 13 close.
For Apnimed, $1,000 at its first-day close on July 31 was $677 at the November 13 close. The table says only what the number became. It does not show that the company put the gain on a different line from the one its own prospectus had named, and had to restate.
Last week's filings
The main filings made from November 9 to November 13 by the companies we follow. For companies that reported results, we include the main numbers.
Apnimed
Nov. 13, 8-K and amended 10-Q: the restatement of April to June described above.
Cerebras
Nov. 12, 8-K and 10-Q: its July to September results. Revenue rose 55% from a year earlier to $210.8 million, and cloud and other services revenue rose 265%. The operating loss was $224.1 million, wider than the $26.5 million loss a year earlier. Cash flows are given for nine months: cash used in operations was $388.9 million and purchases of property and equipment were $1,046.1 million. Remaining performance obligations were $26.1 billion at September 30, up from $24.6 billion at December 31, 2025 in the prospectus. Both filings say a significant amount of the balance was attributable to the agreement with OpenAI.
Andersen
Nov. 12, 8-K and 10-Q: its July to September results. Revenue rose 18.7% from a year earlier to $337.3 million, and operating income was $102.4 million, down from $117.3 million. Consolidated net income was $68.0 million, against $111.1 million a year earlier; after allocating earnings to noncontrolling interests, the net loss attributable to Andersen Group Inc. was $9.0 million. For the nine months, cash from operations was $142.8 million and purchases of property and equipment were $13.7 million. Nov. 13, 8-K: it expects to issue a total of 659,066 unregistered Class A shares as part of the consideration for four acquisitions in Italy, Poland, the US and Spain, about 3.47% of the Class A shares outstanding on November 13.
X-Energy
Nov. 12, 8-K and 10-Q: its July to September results. Revenues and grant income were $66.3 million, up 118% from $30.4 million a year earlier. The operating loss was $103.6 million, wider than the $40.7 million loss a year earlier. Cash used in operations was $51.2 million for the quarter and $215.8 million for the nine months. Nine-month capital expenditures were $178.1 million, of which $80.0 million was reimbursed under a government grant. Total liquidity was $1.8 billion in cash and investments, with no debt. The NRC issued the construction permit for Dow's Long Mott project. Nov. 13, 13G: Van Eck reported 5.6% of the Class A stock.
Freenome
Nov. 10, 8-K, and Nov. 12, 10-Q: its first July to September results as a listed company. Revenue was $183.5 million, against about $1.0 million a year earlier; $180.0 million of it was recognized under its collaboration and license agreement after the FDA approved its SimpleScreen CRC colorectal cancer blood test on July 24. Operating income was $70.0 million, against a loss of $65.3 million a year earlier, and net income was $60.1 million. In the quarter, cash from operations was $38.4 million and purchases of property and equipment were $2.8 million; cash, cash equivalents and marketable securities were $430.0 million at September 30. Nov. 13, 424B3: a supplement attaching the 10-Q to its resale prospectus.
Braveheart Bio
Nov. 10, 8-K and 10-Q: its July to September results. It has no revenue yet. The operating loss was $30.1 million, narrower than the $59.3 million loss a year earlier, which included $58.8 million of acquired in-process research and development. Research and development expense was $17.5 million. For the nine months, cash used in operations was $46.5 million. Cash, cash equivalents and investments were $503.5 million at September 30, which the company expects to fund operations into 2029. Nov. 9, 13G: its partner Jiangsu Hengrui Pharmaceuticals reported 8.2% of the common stock.
Lime
Nov. 12, 10-Q: the quarterly report for the July to September results we covered from its 8-K in the last issue. Net income for the quarter was $43.7 million, against $30.9 million a year earlier. For the nine months, cash from operations was $163.9 million, down from $179.1 million, and purchases of vehicle assets were $142.1 million. Nine-month net income was $277.8 million, driven largely by the release of $289.1 million of the valuation allowance on its US deferred tax assets in April to June.
Anthropic
Nov. 10, Amendment No. 2 to its S-1: a price range of $70.00 to $78.00 per share. The offering is 825,000,000 shares, of which 801,351,354 are new shares and 23,648,646 are sold by existing holders, and the underwriters have an option on another 123,750,000 shares. It has applied to list on Nasdaq under "ANT." Separately, seven companies, AMD, Broadcom, Google, Micron, Microsoft, NVIDIA and TSMC Partners, agreed to buy a total of $26.0 billion of non-voting Class N stock at the IPO price, contingent on the completion of the offering and other conditions. A free writing prospectus filed on November 12 shows that Anthropic has also filed a securities registration statement with Japan's Kanto Regional Finance Bureau, for a Japanese offering of $3.0 billion to $3.5 billion. On November 14 we added Anthropic to the companies awaiting listing on our scoreboard.
Nscale
Nov. 12, Amendment No. 1 to its S-1: it added preliminary estimates for nine months. Estimated revenue for January to September 2026 was $307.5 million, against $21.3 million a year earlier. The estimated operating loss was $837.5 million, against $67.6 million, and the estimated net loss was $1,691.9 million. The price range is still blank; it has applied to list on the NYSE under "NSCL."
Wella
Nov. 13, Amendment No. 2 to its S-1: the company, whose fiscal year ends in June, added July to September. Net revenues rose 4.1% from a year earlier to $738.8 million, and operating income was $84.8 million, up from $61.0 million. Cash used in operations was $103.8 million and capital expenditures were $22.4 million, for free cash flow as the company defines it of minus $126.1 million, against minus $107.7 million a year earlier. The price range is still blank.
FireFly Robotics
Nov. 12, amended S-1: updated to nine months through September. Revenue rose 30.0% from a year earlier to $46.5 million, and the operating loss was $7.1 million, wider than $6.3 million. The net loss was $50.9 million, driven largely by changes in the fair value of convertible debentures of $27.9 million and of warrant liabilities of $15.7 million. Cash used in operations was $6.7 million. It is a direct listing with no new shares sold, planned for Nasdaq under "FFLY."
Meta
Nov. 12, 8-K: it completed a €9.0 billion offering of euro senior notes on November 12, in six series maturing from 2031 to 2065 with rates from 4.300% to 6.400%. The same day it filed to register the notes on Nasdaq.
Reformation
Nov. 13, 13G: founder Yael Aflalo reported 19.75% of the common stock.
Tesla
Nov. 9, DEFA14A: copies of digital advertisements and social media posts ahead of its annual meeting.
Pricings and listings
None among the companies we follow.
New S-1 filings
On November 10, American Barrick Gold, which Barrick Mining is carving out to hold its North American gold mines, filed an S-1. It holds 61.5% of Nevada Gold Mines and 60% of Pueblo Viejo and plans to list on the NYSE under "ABGC." The price range is blank. We have not written about it as of this week. Blue Laser Fusion on November 9 and Agility Robotics on November 10 also filed S-1s, but both register shares for resale and other purposes, not new public offerings. We set aside SPACs, filings by already-listed companies and small offerings from the start.
Get S-1 Journal Weekly in your inbox.
Free. We do not send much. Reply "unsubscribe" to any issue to stop.
See the full scoreboard →Read past issues →S-1 Journal home →